Actelion Pharmaceuticals Ltd

act-050088 - bosentan

 

Study ID Status Type Title
AC-052-321 Completed Results Summary Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study
AC-052-322 Completed Results Summary Open-Label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3
AC-052-332 Completed Results Summary Long-term open-label study in patients with interstitial lung disease associated with systemic sclerosis who completed the protocol AC-052-330
AC-052-333 Completed Results Summary Long-term Bosentan Open Label Extension of the AC-052-331 Study in Systemic Sclerosis Patients With Ischemic Digital Ulcers
AC-052-364 Completed Results Summary A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients with Mildly Symptomatic Pulmonary Arterial Hypertension (PAH)
AC-052-365 Completed Results Summary An open label, multicenter study to assess the pharmacokinetics, tolerability, and safety of a pediatric formulation of bosentan in children with idiopathic or familial pulmonary arterial hypertension
AC-052-366 Completed Results Summary Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
AC-052-367 Completed Results Summary An open label, long-term, safety, and tolerability extension study using the pediatric formulation of bosentan in the treatment of children with idiopathic or familial pulmonary arterial hypertension who completed FUTURE 1
AC-052-370 Completed Results Summary Long-term open-label extension study in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) who completed protocol AC-052-366 (BENEFIT, NCT00313222)
AC-052-371 Completed Results Summary Long-Term, Open-Label, Multicenter, Extension Study of Bosentan in Patients with Pulmonary Hypertension Associated with Sickle Cell Disease Completing a Double-Blind ASSET Study (AC-052-368 or AC 052-369)
1 2